Presenilins and apoptosis in transgenic models of alzheimer's disease

Informations projet

APOPTOSE PRESENILIN

N° de convention de subvention: QLK6-CT-1999-50727

Projet clôturé

Date de début 23 Mars 2001

Date de fin 22 Mars 2005

Financé au titre de

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Coût total € 96 000,00

Contribution de l’UE € 96 000,00

Coordonné par

AVENTIS PHARMA S.A.
France

Objectif

Characterization of the signalling cascade involved in the increased sensitivity to apoptosis in primary culture of mutant presently transgenic mice.

Champ scientifique

• medical and health sciences › basic medicine › neurology › dementia › alzheimer

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Thème(s)

• 1.1.1.-6. - Key action The Ageing Population and Disabilities

Appel à propositions

Data not available

Régime de financement

BUR - Bursaries, grants, fellowships

Coordinateur

AVENTIS PHARMA S.A.

• Contribution de l’UE: Aucune donnée
• Adresse: Quai Jules Guesde, 13 ; 94403 VITRY SUR SEINE ; France
• Coût total: Aucune donnée